±j®Ä§Ü¥Í¯À³B¤è ¤@¦¨µû¡u¤£¦X¾A¡v
¡i©ú³ø±M°T¡j¤£·í¨Ï¥Î§Ü¥Í¯À¥i«P¨Ï§ó¦h§ÜÃÄ´cµß¥X²{¡CÂåºÞ§½2017¦~°_±À¦æp¹º¡AÂЮ֤º¬ì¡B¥~¬ì©M°©¬ìªº±j®Ä§Ü¥Í¯À³B¤è¡A¥h¦~¦³12.4%³Qµû¤£¦X¾A¡C
¦b¦³Ãöp¹º¤¤¡A¨C·í¯f¤HÀò³B¤è±`¥Î±j®Ä§Ü¥Í¯À¡u¬üù°ö«n(Meropenem)¡v©Î¡u‹Q©Ô¦èªL¢A¥LÐü¤Ú©Z(Piperacillian/Tazobactam)¡v®É¡A³£·|¥Ñ·L¥Íª«¬ì©Î¶Ç¬V¯f¬ìÂå¥ÍÂЮֳB¤è¬O§_¦X¾A¡AY¤£¦X¾A¡A´N·|¦V¬ÛÃöÂå¥Í´£¨Ñ«Øij¡C¥h¦~¦³87.6%§Ü¥Í¯À³B¤è³Qµû¬°¦X¾A¡A12.4%Äݤ£¦X¾A¡FÀò´£¨Ñ³B¤è«ØijªºÓ®×¤¤¡A86.7%Âå¥Í±µ¨ü«Øij¡A§ï¥Î©Î°±¥Î§Ü¥Í¯À¡A13.3%¤£±µ¨ü«Øij¡C
¦óüø¨}¡G¥~°ê¨â¦¨°¾Â÷«ü¤Þ ´äÄݲz·Q
ÂåºÞ§½Á`·P¬V±±¨î¥D¥ô¿à°¶¤å»¡¡A¥h¦~³B¤è¦X¾Aªº¤ñ²v¡A°ª©ó«e¦~ªº¬ù85%¡A¤Ï¬Mp¹º¦³¦¨®Ä¡C¥L»¡p¹º¤¤µo²{³¡¤ÀÂå¥Í¨S«ö¤ÆÅç³ø§iÂà¥Î§Ü¥Í¯À©Î´î¤Ö³B¤è®É¶¡¡A¦Ó¤£±µ¨üÂЮ֫ØijÂå¥Í¤¤¡A³¡¤À¤H·|»{¬°³B¤è¦h¸û³B¤è¤ÖÃĦn¡A·|¥[±j±Ð¨|¡C
´ä¤j·P¬V¤Î¶Ç¬V¯f¤¤¤ßÁ`ºÊ¦óüø¨}ºÙ¡A¥~°êÃþ¦üÂЮֵ²ªG¬O¨â¦¨¦Ü¤T¦¨³B¤è°¾Â÷§Ü¥Í¯À«ü¤Þ¡A¥»´äªñ90%²Å¦X«ü¤ÞÄÝ¡u«Ü²z·Q¡v¡A¥L¤S»¡ªvÀøÄY«·P¬VӮ׮ɡA¬Y¨Ç±¡úG¤U¡u¥i¯àn«¤â¤p¤pð}ÂI¡v¡C